These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15951170)

  • 1. Isomeric thiazole derivatives as ligands for the neuropeptide Y5 receptor.
    Nettekoven M; Guba W; Neidhart W; Mattei P; Pflieger P; Roche O; Taylor S
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3446-9. PubMed ID: 15951170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel and potent NPY5 receptor antagonists derived from virtual screening and iterative parallel chemistry design.
    Guba W; Neidhart W; Nettekoven M
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1599-603. PubMed ID: 15745805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pharmacological evaluation of thiazole and isothiazole derived apomorphines.
    Sipos A; Mueller FK; Lehmann J; Berényi S; Antus S
    Arch Pharm (Weinheim); 2009 Oct; 342(10):557-68. PubMed ID: 19714675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
    Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
    J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-(thiazol-2-yl)-2-thiophene carboxamide derivatives as Abl inhibitors identified by a pharmacophore-based database screening of commercially available compounds.
    Manetti F; Falchi F; Crespan E; Schenone S; Maga G; Botta M
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4328-31. PubMed ID: 18621522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel potent neuropeptide Y Y5 receptor antagonists: synthesis and structure-activity relationships of phenylpiperazine derivatives.
    Takahashi T; Sakuraba A; Hirohashi T; Shibata T; Hirose M; Haga Y; Nonoshita K; Kanno T; Ito J; Iwaasa H; Kanatani A; Fukami T; Sato N
    Bioorg Med Chem; 2006 Nov; 14(22):7501-11. PubMed ID: 16919461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay.
    Beauverger P; Rodriguez M; Nicolas JP; Audinot V; Lamamy V; Dromaint S; Nagel N; Macia C; Léopold O; Galizzi JP; Caignard DH; Aldana I; Monge A; Chomarat P; Boutin JA
    Cell Signal; 2005 Apr; 17(4):489-96. PubMed ID: 15601626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminothiazole derivatives as neuropeptide Y5 receptor ligands: finding the balance between affinity and physicochemical properties.
    Nettekoven M; Guba W; Neidhart W; Mattei P; Pflieger P; Plancher JM; Taylor S
    ChemMedChem; 2006 Jan; 1(1):45-8. PubMed ID: 16892333
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Moreno A; Pérez S; Galiano S; Juanenea L; Erviti O; Frígola C; Aldana I; Monge A
    Eur J Med Chem; 2004 Jan; 39(1):49-58. PubMed ID: 14987833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative structure activity relationship of benzoxazinone derivatives as neuropeptide Y Y5 receptor antagonists.
    Deswal S; Roy N
    Eur J Med Chem; 2006 Apr; 41(4):552-7. PubMed ID: 16545499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cis-1-Oxo-heterocyclyl-4-amido cyclohexane derivatives as NPY5 receptor antagonists.
    Burns JF; Chen B; Chen CA; Doller D; Edelmenky E; Jiang Y; Peterson JM; Sabio M; Weiss J; White AD; Wu L; Bhardwaj R; Chandrasena G; Boyle NJ; Huang X
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1458-61. PubMed ID: 24582476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent argininamide-type neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation.
    Keller M; Teng S; Bernhardt G; Buschauer A
    ChemMedChem; 2009 Oct; 4(10):1733-45. PubMed ID: 19672917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.
    Mashiko S; Moriya R; Ishihara A; Gomori A; Matsushita H; Egashira S; Iwaasa H; Takahashi T; Haga Y; Fukami T; Kanatani A
    Eur J Pharmacol; 2009 Aug; 615(1-3):113-7. PubMed ID: 19482021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity.
    Walker MW; Wolinsky TD; Jubian V; Chandrasena G; Zhong H; Huang X; Miller S; Hegde LG; Marsteller DA; Marzabadi MR; Papp M; Overstreet DH; Gerald CP; Craig DA
    J Pharmacol Exp Ther; 2009 Mar; 328(3):900-11. PubMed ID: 19098165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tautomeric modification of GlcNAc-thiazoline.
    Knapp S; Abdo M; Ajayi K; Huhn RA; Emge TJ; Kim EJ; Hanover JA
    Org Lett; 2007 Jun; 9(12):2321-4. PubMed ID: 17508759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CH...O and CH...N hydrogen bonds in ligand design: a novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor.
    Pierce AC; ter Haar E; Binch HM; Kay DP; Patel SR; Li P
    J Med Chem; 2005 Feb; 48(4):1278-81. PubMed ID: 15715498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element.
    Haginoya N; Kobayashi S; Komoriya S; Yoshino T; Suzuki M; Shimada T; Watanabe K; Hirokawa Y; Furugori T; Nagahara T
    J Med Chem; 2004 Oct; 47(21):5167-82. PubMed ID: 15456260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel range based QSAR study of human neuropeptide Y (NPY) Y5 receptor inhibitors.
    Deswal S; Roy N
    Eur J Med Chem; 2007 Apr; 42(4):463-70. PubMed ID: 17083999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
    Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.